MxA protein induction in MS patients treated with intramuscular IFNbeta-1a
| Autor: | Salmi Aa, Erälinna Jp, A.-M. Vallittu |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Myxovirus Resistance Proteins medicine.medical_specialty Antigenicity Neurology Multiple Sclerosis Gene Expression Stimulation Dermatology Pharmacology Injections Intramuscular Disability Evaluation Adjuvants Immunologic GTP-Binding Proteins medicine Mxa protein Humans Dosing biology business.industry Multiple sclerosis General Medicine Interferon-beta Middle Aged medicine.disease Flow Cytometry Virology Peripheral blood Psychiatry and Mental health biology.protein Female Neurology (clinical) Antibody business Follow-Up Studies |
| Zdroj: | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 26(6) |
| ISSN: | 1590-1874 |
| Popis: | MxA protein production in peripheral blood leukocytes is a valuable marker to evaluate biologic effects of interferon-beta (IFNbeta) therapy in multiple sclerosis (MS) patients. The three IFNbeta preparations available in the treatment of MS differ with respect to antigenicity and biologic activity. We studied prospectively the induction of MxA protein and the development of binding (BAb) and neutralising antibodies (NAb) in nine relapsing-remitting MS (RRMS) patients during one year of intramuscular IFNbeta -1a (Avonex) treatment. Another nine RRMS patient treated with Avonex for 1-3.5 years were also included. The results were compared with our earlier published data of subcutaneous IFNbeta-1a (Rebif). None of these 18 patients developed NAb but three of the long-term patients developed BAb. The baseline MxA protein levels rose but the induction was weaker compared to Rebif. The stimulation index (MxA after/before IFNbeta-1a injection) remained elevated. Weekly intramuscular dosing of IFNbeta-1a provides a sustained effect on lymphocytes but differences in leukocyte stimulation may underlie some of the differences between IFNbeta therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink